

Leaders
in Trusted
Technologies

NISSHA

Financial Results
for FY2026 Q1
Ended March 31, 2026


May 12, 2026

Junya Suzuki

Chairman of the Board and Group CEO
Nissha Co., Ltd.

Change in Reportable Segments

- Medical Technologies and Pharmaceuticals integrated into the "Medical" segment



FY2026 Q1 Results

- Consolidated: Net sales exceeded the previous forecast, operating profit turned positive
- Industrial Materials, Devices: Performance exceeded the previous forecast, operating profit improved
- Medical: Demand for medical devices (CDMO), OTC pharmaceuticals (CDMO) remained solid

Forecast for FY2026

- H1 revised upward, reflecting Q1 outperformance
- Q2-Q4: Cost increase risks factored into the forecast, related to the Middle East situation
- Full-year net sales 198.0 billion yen, operating profit 7.0 billion yen, profit attributable to owners of parent 3.2 billion yen
- Assumed exchange rate: Q2 JPY155/USD (initial plan JPY145/USD), H2 JPY145/USD (initial plan maintained)

Topics

- Change in reportable segments (see previous page)

FY2026 Q1 (3 months) Results

Leaders in Trusted Technologies

(Millions of JPY)

	2025 Q1 Results	2025 Q4 Results	2026 Q1 Previous forecast	2026 Q1 Results	YoY	QoQ	vs. Previous forecast
Net sales	47,442	49,627	40,800	45,790	-3.5%	-7.7%	+12.2%
Industrial Materials	18,785	19,240	17,600	19,529	+4.0%	+1.5%	+11.0%
Devices	13,558	14,625	9,000	10,400	-23.3%	-28.9%	+15.6%
Medical	13,625	13,973	12,700	14,134	+3.7%	+1.2%	+11.3%
Medical devices	11,948	12,083	11,000	12,337	+3.2%	+2.1%	+12.2%
Pharmaceuticals	1,676	1,890	1,700	1,797	+7.2%	-4.9%	+5.7%
Others	1,473	1,787	1,500	1,727	+17.2%	-3.4%	+15.1%
Operating profit	1,432	532	✓ -500	✓ 750	-47.6%	+41.0%	✓ Turn positive
Operating profit margin	3.0%	1.1%	-1.2%	1.6%	-1.4pt	+0.5pt	+2.8pt
Industrial Materials	1,012	747	✓ 300	✓ 708	-30.1%	-5.2%	✓ +136.0%
Devices	865	663	✓ -300	✓ 392	-54.6%	-40.8%	✓ Turn positive
Medical	742	✓ 489	800	✓ 841	+13.3%	✓ +71.9%	+5.1%
Others	-171	-147	0	99	Turn positive	Turn positive	-
Reconciliations	*1 -1,016	*3 -1,220	-1,300	*5 -1,290	-	-	-
Profit before tax	*2 592	*4 1,337	-850	*6 751	+26.8%	-43.8%	Turn positive
Profit attributable to owners of parent	12	496	-1,400	422	+3,358.6%	-14.8%	Turn positive
Forex (Average)	¥153/\$	¥150/\$	¥145/\$	¥155/\$			
Forex (End of previous period → End of current period)	¥158/\$→¥150/\$	¥149/\$→¥157/\$		¥157/\$→¥160/\$			


*1 Forex loss 0.25 bn yen included *2 Forex loss (finance costs) 0.5 bn yen included *3 Legacy equipment impairment loss 0.7 bn yen (restart of Tsu factory) and forex gain 0.3 bn yen included *4 Fair value measurement gain on financial liabilities 0.65 bn yen and forex gain (finance income) 0.55 bn yen included *5 Forex loss 0.05 bn yen included *6 Forex gain (finance income) 0.35 bn yen included

Industrial Materials: Q1 Results, Q2 Forecast (QoQ)

Quarterly net sales and operating profit margin

- Sustainable Materials (Metallized paper and others)
- Decoration (Home appliances and others)
- Decoration (Mobility)
- Operating profit margin

(Millions of JPY)



● Q1 Results (Forex: JPY155/\$)

- Decoration: Steady demand continued both in mobility and home appliances
- Sustainable Materials (Metallized paper): Demand recovery trend
- Operating profit: Exceeded the previous forecast

● Q2 Forecast (Assumed Forex: JPY155/\$)


- Decoration: Demand for mobility and home appliances to remain stable
- Sustainable Materials: Recovery trend to continue
- Operating profit: To be improved through higher demand

Devices: Q1 Results, Q2 Forecast (QoQ)

Quarterly net sales and operating profit margin

- Handheld terminals (logistics related) and others
- Tablet devices and others
- Operating profit margin

(Millions of JPY)



- Q1 Results (Forex: JPY155/\$)
 - Tablet devices: Despite significant decline, exceeded the previous forecast
 - Operating profit: The impact of demand decrease mitigated by production leveling and profitability secured, exceeded the previous forecast


- Q2 Forecast (Assumed Forex: JPY155/\$)
 - Tablet devices: Demand recovery
 - Handheld terminals: Steady demand to continue
 - Operating profit: Acquisition-related costs (0.13 billion yen) to be recorded

Medical: Q1 Results, Q2 Forecast (QoQ)

Quarterly net sales and operating profit margin

- Pharmaceuticals (CDMO)
- Medical devices (Own brand)
- Business media
- Medical devices (CDMO)
- Operating profit margin

(Millions of JPY)



- Q1 Results (Forex: JPY155/\$)
 - Medical devices (CDMO): Demand remained solid
 - OTC Pharmaceuticals CDMO: Demand remained solid
 - Operating profit: Profitability improved with temporary costs decreased from the previous quarter, as expected
- Q2 Forecast (Assumed Forex: JPY155/\$)
 - Medical devices (CDMO): Demand to grow
 - OTC Pharmaceuticals CDMO: Same as the previous forecast, lower operation due to equipment renewal
 - Operating profit: Same as the previous forecast

FY2026 Forecast

Leaders in Trusted Technologies

(Millions of JPY)

	Previous Forecast (February 12)			Revised Forecast (May 12)		
	FY2026 Full-year Forecast	FY2026 H1 Forecast	FY2026 H2 Forecast	FY2026 Full-year Forecast	FY2026 H1 Forecast	FY2026 H2 Forecast
Net sales	191,500	87,500	104,000	198,000	94,000	104,000
Industrial Materials	78,600	37,000	41,600	81,400	39,800	41,600
Devices	52,600	21,900	30,700	54,000	23,300	30,700
Medical	54,600	25,900	28,700	56,800	28,100	28,700
Medical devices	47,200	22,700	24,500	49,300	24,800	24,500
Pharmaceuticals	7,400	3,200	4,200	7,500	3,300	4,200
Others	5,700	2,700	3,000	5,800	2,800	3,000
Operating profit	6,600	900	5,700	7,000	1,800	5,200
Operating profit margin	3.4%	1.0%	5.5%	3.5%	1.9%	5.0%
Industrial Materials	4,000	1,200	2,800	4,200	1,600	2,600
Devices	2,600	300	2,300	3,000	900	2,100
Medical	4,300	1,800	2,500	4,200	1,800	2,400
Others	-200	-100	-100	-200	-100	-100
Reconciliations	-4,100	-2,300	-1,800	-4,200	-2,400	-1,800
Profit before tax	5,000	100	4,900	5,700	1,300	4,400
Profit attributable to owners of parent	2,300	-1,100	3,400	3,200	300	2,900
Forex (Average)	¥145/\$	¥145/\$	¥145/\$	¥150/\$	¥155/\$	¥145/\$

Investor Conference

Reinforcing and Rationalizing the Business Portfolio /Medical Device CDMO Update

- Date and time
 - July 7, Tuesday, 11:00 a.m. - 12:30 p.m.
- Meeting format
 - On-site and live streaming
- Venue
 - Shin Marunouchi Building Conference Square
- Attendees
 - Junya Suzuki, Chairman of the Board and Group CEO
 - Wataru Watanabe, Director of the Board, Senior Executive Vice President, Chief Strategy Officer
 - Brandon Hoffman, Senior Vice President, CEO of Nissha Medical Technologies
 - Ryuhei Sakaguchi, Director, Corporate Communications

(Reference)
Capital investment, Depreciation and amortization,
M&A investment, R&D (FY2026)

(Millions of JPY)

	Q1 Results
Capital investment	2,334
Depreciation and amortization	2,562
M&A investment	648
R&D	766

Leaders in Trusted Technologies

Among the information included in this presentation and provided at investor briefings and conferences, performance targets, plans, outlooks, strategies and other information that is not constituted of actual past facts, is information that has been judged reasonable by the managers of the Company based on the information available at the time of its creation and contains elements of risk and uncertainty. Actual business results may differ greatly depending on various factors such as economic trends, market demand, and fluctuations in exchange rates.